Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 5/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | PLG | P00747 | 2/20 | 0.35 |
| ▸ | PLAU | P00749 | 2/20 | 0.35 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | MC2R | Q01718 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509562 | 0.93 | KMT2A (0.45) | KMT2AMEN1PBKNAMPTF10 | |
| SCHEMBL14091684 | 0.92 | PBK (0.40) | KMT2AMEN1PBKNAMPTF10 | |
| SCHEMBL12834094 | 0.83 | MC2R (0.36) | NAMPTRAD52UHRF1F10PLG | |
| SCHEMBL1509555 | 0.83 | PLG (0.42) | F10PLGPLAUKITF2 | |
| SCHEMBL14091687 | 0.83 | PLG (0.43) | F10PLGPLAUF2PLAT | |
| Hydrochloric Acid SCHEMBL1509637 | 0.82 | F10 (0.42) | F10PLGPLAUF2PLAT | |
| SCHEMBL1509477 | 0.79 | F10 (0.38) | NAMPTF10PLGPLAUF2 | |
| SCHEMBL1509505 | 0.76 | NAMPT (0.36) | NAMPTF10PLGPLAUF2 | |
| SCHEMBL12834421 | 0.75 | CARM1 (0.36) | NAMPTF10PLGPLAUF2 | |
| SCHEMBL4754559 | 0.74 | PLG (0.51) | F10PLGPLAUF2PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| EP-2298770-A1 | Heterocyclic compounds as TrkA modulators | ChemBridge Corporation (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| WO-2007056155-A1 | HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | KMT2A 1726/4885MEN1 1879/4885PBK 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.